Junshi Biosciences’ JunMaiKang Approved by NMPA for Multiple Indications
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that its JunMaiKang, a biosimilar version...
SHA: 688180
Junshi Biosciences Launches PD-1 Inhibitor Tuoyi for Advanced NSCLC in China
Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has held a national market...
Junshi Biosciences’ Tuoyi Approved for First-Line NSCLC Treatment in China
China’s Center for Drug Evaluation (CDE) has approved Junshi Biosciences’ (HKG: 1877, SHA: 688180) Tuoyi...
Junshi Biosciences Plans USD 572M Private Placement to Fund Drug R&D and Expansion
China’s Shanghai Junshi Biosciences Co., Ltd (SHA: 688180, HKG: 1877) announced plans to raise up...
Junshi Biosciences’ TAB009/JS009 and JS110 Advance in Cancer Trials
Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration...
Junshi Biosciences Gets NMPA Go-Ahead for TAB009/JS009 Cancer Study
Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration...
Junshi Biosciences’ JunMaiKang Biosimilar Gets NMPA Approval Filing
China-based Junshi Biosciiences (HKG: 1877, SHA: 688180) has announced that another market approval filing for...
Junshi Biosciences’ Toripalimab Receives EC Orphan Drug Designation for NPC
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that its PD-1 inhibitor Toripalimab (trade name:...
Junshi Biosciences’ JS203 Bispecific Antibody Receives NMPA Green Light for NHL Study
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the National Medical Products Administration (NMPA)...
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Under FDA Review for NPC Treatment
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the Biologics License Application (BLA) for...
Junshi Biosciences Receives FDA Approval for PI3K-α Inhibitor RP903 in Breast Cancer Study
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) announced that it has received approval from the...
Junshi Biosciences Receives NMPA Approval for Fourth-Generation EGFR Inhibitor WJ13404
Shanghai-based biotech Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from China’s National Medical...